Skip to main content
Premium Trial:

Request an Annual Quote

DuPont Pharma And SBI Ally For Genes-To-Leads

Premium

SAN DIEGO--DuPont Pharmaceuticals, a component of DuPont's Life Science Enterprise, and privately held Structural Bioinformatics last week announced a strategic alliance for the discovery and development of small-molecule leads in a family of signaling proteins and other targets. The alliance is a multiyear agreement involving certain guaranteed and milestone payments with an overall value in excess of $100 million, assuming several successful products.

Under the terms of the agreement, DuPont will pay for technology access and for research support at Structural Bioinformatics. The two companies will collaborate to identify and optimize lead molecules targeted at receptors for several signaling proteins.

"SBI's approach is a cutting-edge attempt to address the challenging problem of interrupting protein-protein interactions," said Paul Friedman, president of DuPont Pharmaceuticals Research Laboratories.

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.